Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor Positive Breast Carcinoma
HER2-negative Breast Cancer
PIK3CA Mutant Metastatic Breast Cancer

Interventions

DRUG: Alpelisib
DRUG: Fulvestrant
DRUG: Aromatase inhibitor

Sponsor

Marina N Sharifi

Collaborators

[object Object]
[object Object]